inflammatory rheumatic diseases such as rheumatoid arthritis, post-traumatic osteoarthritis, arthritis in systemic connective tissue diseases; degenerative rheumatic diseases, especially in the presence of inflammation of the synovial membrane of the joint; extra-articular rheumatism: fascitis, inflammation and dystrophy of tendon tissues, rheumatic polymyalgia, acute bursitis; Dermatology diseases: atopic dermatitis, neurodermatitis, urticaria, alopecia, psoriasis, herpetic dermatitis; allergic reactions such as bronchial asthma, severe allergic bronchitis, rhinitis, angioedema, contact dermatitis; oncological diseases: palliative therapy of leukemia and lymphoma in adults, acute leukemia in children; primary and secondary adrenal insufficiency; nephritis, nephropathic syndrome
Flosteron Pharmacological properties
Pharmacodynamics. betamethasone is a synthetic corticosteroids with anti-inflammatory and immunosuppressive activity. in addition, it acts on energy metabolism, glucose homeostasis and (through negative feedback) on the secretion of hypothalamic releasing factor and adenohypophysis hormones.
Steroids with one double bond in ring A and other substituents C (16) in ring D, 9-alpha-fluorine derivatives, have a pronounced corticosteroid effect. These C (16) substituents actually reduce the mineralocorticoid effect.
• rheumatoid arthritis, osteoarthritis, bursitis, tendosynovitis, tendinitis, peritendinitis, ankylosing spondylitis, epicondylitis, sciatica, coccidinia, sciatica, lumbago, torticollis, ganglion cyst, exostosis, fasciitis, palpation, bruising feet.
• BA, status asthmaticus, hay fever, allergic bronchitis, allergic rhinitis, drug allergies, serum sickness, reactions to insect bites.
• Atopic dermatitis (coin-like eczema), neurodermatitis, contact dermatitis, severe solar dermatitis, urticaria, lichen planus, insulin lipodystrophy, alopecia areata, discoid erythematous lupus erythematosus, psoriasis, keloid scars, cystic dermatitis vulgaris, herpes simplex.
• Systemic lupus erythematosus, scleroderma, dermatomyositis, periarteritis nodosa.
• Palliative therapy for leukemia and lymphomas in adults; acute leukemia in children.
• Adrenogenital syndrome, ulcerative colitis, regional ileitis, sprue; pathological changes in the blood requiring corticosteroid therapy, nephritis, nephrotic syndrome.
• Primary and secondary adrenal cortex insufficiency (with the obligatory simultaneous use of mineralocorticoids).
If necessary, systemic use of GCS phlosterone is recommended to be administered intramuscularly. also used intra-articular and periarticular administration for arthritis, local injections into the lesion or intradermal administration for diseases of the skin and feet.
The dosage regimen and the route of administration are set individually depending on the indications, the severity of the disease and the clinical response to therapy. The dose should be minimal and the period of use is as short as possible.
If a satisfactory clinical effect is not achieved within a certain period of time, treatment with the drug should be discontinued and another appropriate therapy should be carried out.
With systemic therapy, the initial dose of the drug in most cases is 1-2 ml. If necessary, depending on the patient’s condition, the introduction is repeated. The drug is injected deep intramuscularly into the buttock:
– in severe conditions (systemic lupus erythematosus and status asthmaticus) requiring emergency measures, the initial dose of the drug may be 2 ml;
– for various dermatological diseases, 1 ml of the drug is usually sufficient;
– in diseases of the respiratory system (BA, hay fever, allergic bronchitis and allergic rhinitis), a significant improvement in the condition is achieved after administration of 1–2 ml of the drug. The action of the drug begins within a few hours after i / m injection.